Pembrolizumab plus nab-paclitaxel and platinum as first-line treatment in patients with recurrent or metastatic head and neck squamous-cell carcinoma (R/M HNSCC): A prospective phase II study

被引：0
|
作者：
Gui, L. [1 ]
Chen, X. [2 ]
He, X. [1 ]
Yang, J. [3 ]
Liu, P. [1 ]
Qin, Y. [1 ]
Shi, Y-K. [4 ]
机构：
[1] Chinese Acad Med Sci & Peking Union Med Coll, Canc Hosp, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Beijing Key Lab Clin Study Anticancer Mol Targete, Natl Clin Res Ctr Canc, Canc Hosp,Natl Canc Ctr,Dept Med Oncol, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, CAMS PUMC, Dept Med Oncol, Beijing, Peoples R China
[4] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Dept Med Oncol, Beijing, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2023年 / 34卷
关键词：
D O I：
10.1016/j.annonc.2023.10.468
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
360MO
引用
收藏
页码：S1609 / S1610
页数：2
相关论文
共 50 条
  • [11] Phase II study of the combination of cetuximab and weekly paclitaxel in the first-line treatment of patients with recurrent and/or metastatic squamous cell carcinoma of head and neck
    Hitt, R.
    Irigoyen, A.
    Cortes-Funes, H.
    Grau, J. J.
    Garcia-Saenz, J. A.
    Cruz-Hernandez, J. J.
    ANNALS OF ONCOLOGY, 2012, 23 (04) : 1016 - 1022
  • [12] LEAP-010: Phase III study of first-line pembrolizumab with or without lenvatinib in patients (pts) with recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Siu, L. L.
    Burtness, B.
    Cohen, E. E.
    Harrington, K. J.
    Licitra, L. F.
    Rischin, D.
    Zhu, Y.
    Okpara, C. E.
    Pinheiro, C.
    Swaby, R. F.
    Machiels, J-P.
    Tahara, M.
    ANNALS OF ONCOLOGY, 2020, 31 : S683 - S684
  • [13] Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
    Liu, Yuan
    Fang, Shan-shan
    Zhao, Run-sheng
    Liu, Bo
    Jin, Yi-qiang
    Li, Quan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2024, 150 (06)
  • [14] CARBOPLATIN, PACLITAXEL AND PEMBROLIZUMAB FOR THE FIRST LINE TREATMENT OF RECURRENT AND/OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA
    Valadez, Angelica
    Welsh, Madeleine
    Kim, Christine
    Johns, Angela
    Algazi, Alain
    Kang, Hyunseok
    Kang, Hyunseok
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 : A118 - A118
  • [15] Pembrolizumab with or Without Lenvatinib As First-line Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC): Phase 3 LEAP-010 Study
    Licitra, L.
    Tahara, M.
    Harrington, K.
    Hurtado de Mendoza, M. Olivera
    Guo, Y.
    Aksoy, S.
    Fang, M.
    Zurawski, B.
    Csoszi, T.
    Klochikhin, M.
    de Oliveira, T. B.
    Takahashi, S.
    Yang, M. H.
    Swiecicki, P. L.
    O'Hara, K.
    Shen, J.
    Wang, A.
    Gumuscu, B.
    Benjamin, K.
    Haddad, R. I.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 118 (05): : E2 - E3
  • [16] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [17] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in patients with recurrent/metastatic (r/m) head and neck squamous cell carcinoma (HNSCC).
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios Dimitrios
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [18] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan
    Katabi, Nora
    Sima, Camelia
    Kelly, Katherine W.
    Nwankwo, Oby
    Haque, Sofia
    Pfister, David G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
  • [19] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G. Fury
    Eric Sherman
    Alan Ho
    Nora Katabi
    Camelia Sima
    Katherine W. Kelly
    Oby Nwankwo
    Sofia Haque
    David G. Pfister
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 121 - 128
  • [20] Platinum/taxane/pembrolizumab vs platinum/5FU/pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma (r/m HNSCC)
    Sun, Lova
    Cohen, Roger B.
    Colevas, A. Dimitrios
    ORAL ONCOLOGY, 2024, 158
12345